Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaratumab - Eli Lilly and Company

Next Previous
Drug Profile

Olaratumab - Eli Lilly and Company

Alternative Names: IMC-3G3; LARTRUVO; LY-3012207

Latest Information Update: 27 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly and Company
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Platelet-derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Discontinued Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 16 Dec 2024 Eli Lilly and Company completes an expanded-access programme for Soft tissue sarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Austria, Brazil, Canada, Hungary, India, Italy, South Korea, Spain, Taiwan, United Kingdom and USA (NCT03994627)
  • 13 Sep 2024 Discontinued - Phase-I for Solid tumours (In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in Japan, USA (IV) prior to September 2024 (Eli Lilly and Company pipeline, September 2024)
  • 27 Jun 2024 Eli Lilly completes the phase III ANNOUNCE trial for Soft tissue sarcoma (Combination therapy, Late-stage disease) in Argentina, Austria, Brazil, Denmark, Finland, Hungary, Israel, Italy, Mexico, South Korea, Spain, Sweden, Taiwan, USA, Australia, Belgium, Canada, France, Germany, Japan, Netherlands, Poland, Russia, Switzerland and United Kingdom (NCT02451943)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top